{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T07:42:55Z","timestamp":1791272575735,"version":"4.1.0"},"update-to":[{"DOI":"10.1002\/14651858.cd010677","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2019,3,28]],"date-time":"2019-03-28T00:00:00Z","timestamp":1553731200000}}],"reference-count":249,"publisher":"Wiley","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd010677.pub2","type":"journal-article","created":{"date-parts":[[2019,3,28]],"date-time":"2019-03-28T14:21:42Z","timestamp":1553782902000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["Benzodiazepines versus placebo for panic disorder in adults"],"prefix":"10.1002","author":[{"given":"Johanna","family":"Breilmann","sequence":"first","affiliation":[{"name":"Ulm University; Department of Psychiatry II; Ludwig-Heilmeyer-Str. 2 Guenzburg Germany 89312"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Girlanda","sequence":"additional","affiliation":[{"name":"Ulm University; Department of Psychiatry II; Ludwig-Heilmeyer-Str. 2 Guenzburg Germany 89312"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Guaiana","sequence":"additional","affiliation":[{"name":"Western University; Department of Psychiatry; Saint Thomas Elgin General Hospital 189 Elm Street St Thomas ON Canada N5R 5C4"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corrado","family":"Barbui","sequence":"additional","affiliation":[{"name":"University of Verona; Department of Neurosciences, Biomedicine and Movement Sciences, Section of Psychiatry; Verona Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Cipriani","sequence":"additional","affiliation":[{"name":"University of Oxford; Department of Psychiatry; Warneford Hospital Oxford UK OX3 7JX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariasole","family":"Castellazzi","sequence":"additional","affiliation":[{"name":"University of Verona; Department of Neurosciences, Biomedicine and Movement Sciences, Section of Psychiatry; Verona Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Bighelli","sequence":"additional","affiliation":[{"name":"Klinikum rechts der Isar, Technische Universit\u00e4t M\u00fcnchen; Department of Psychiatry and Psychotherapy; Ismaningerstr. 22 Munich Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon JC","family":"Davies","sequence":"additional","affiliation":[{"name":"University of Toronto; Geriatric Psychiatry Division, CAMH; 6th Floor, 80 Workman Way Toronto Canada M6J 1H4"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshi A","family":"Furukawa","sequence":"additional","affiliation":[{"name":"Kyoto University Graduate School of Medicine\/School of Public Health; Department of Health Promotion and Human Behavior; Yoshida Konoe-cho, Sakyo-ku, Kyoto Japan 606-8501"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Koesters","sequence":"additional","affiliation":[{"name":"Ulm University; Department of Psychiatry II; Ludwig-Heilmeyer-Str. 2 Guenzburg Germany 89312"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2019,3,28]]},"reference":[{"issue":"6","key":"10.1002\/14651858.CD010677.pub2-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1177\/070674370304800604","article-title":"Correlates of therapeutic response in panic disorder presenting with palpitations: heart rate variability, sleep, and placebo effect","volume":"48","author":"Baker","year":"2003","journal-title":"Canadian Journal of Psychiatry\/Revue Canadienne de Psychiatrie"},{"issue":"2","key":"10.1002\/14651858.CD010677.pub2-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1097\/00004714-199404000-00005","article-title":"Clonazepam in the treatment of panic disorder: a double-blind, placebo-controlled trial investigating the correlation between clonazepam concentrations in plasma and clinical response","volume":"14","author":"Beauclair","year":"1994","journal-title":"Journal of Clinical Psychopharmacology"},{"issue":"5","key":"10.1002\/14651858.CD010677.pub2-BIB0003|cit3","first-page":"202","article-title":"Adinazolam-SR in panic disorder with agoraphobia: relationship of daily dose to efficacy","volume":"56","author":"Carter","year":"1995","journal-title":"Journal of Clinical Psychiatry"},{"issue":"8","key":"10.1002\/14651858.CD010677.pub2-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1176\/ajp.150.8.1219","article-title":"Evidence that decreased function of lymphocyte beta adrenoreceptors reflects regulatory and adaptive processes in panic disorder with agoraphobia","volume":"150","author":"Maddock","year":"1993","journal-title":"American Journal of Psychiatry"},{"issue":"5","key":"10.1002\/14651858.CD010677.pub2-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1111\/j.1600-0447.1990.tb01401.x","article-title":"Drug treatment of panic disorder: early response to treatment as a predictor of final outcome","volume":"82","author":"Albus","year":"1990","journal-title":"Acta Psychiatrica Scandinavica"},{"issue":"3","key":"10.1002\/14651858.CD010677.pub2-BIB0006|cit6","first-page":"145","article-title":"Panic disorder: a five-year follow-up study in 52 patients","volume":"11","author":"Andersch","year":"1997","journal-title":"European Journal of Psychiatry"},{"issue":"8","key":"10.1002\/14651858.CD010677.pub2-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.eurpsy.2003.03.007","article-title":"A 15-year follow-up study of patients with panic disorder","volume":"18","author":"Andersch","year":"2003","journal-title":"European Psychiatry"},{"key":"10.1002\/14651858.CD010677.pub2-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1111\/j.1600-0447.1991.tb03097.x","article-title":"Efficacy and safety of alprazolam, imipramine and placebo in treating panic disorder. A Scandinavian multicenter study","volume":"365","author":"Andersch","year":"1991","journal-title":"Acta Psychiatrica Scandinavica, Supplementum"},{"issue":"1","key":"10.1002\/14651858.CD010677.pub2-BIB0009|cit9","first-page":"1","article-title":"Pharmacologic treatment of panic disorders: comparative report on the efficacy and safety of alprazolam and imipramine in a controlled study","volume":"14","author":"Berlanga","year":"1991","journal-title":"Salud Mental"},{"key":"10.1002\/14651858.CD010677.pub2-BIB0010|cit10","first-page":"449","article-title":"Treatment of panic disorder","volume":"47","author":"Cassano","year":"1992","journal-title":"Advances in Biochemical Psychopharmacology"},{"issue":"1","key":"10.1002\/14651858.CD010677.pub2-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/0924-977X(94)90314-X","article-title":"Adverse effects associated with the short-term treatment of panic disorder with imipramine, alprazolam or placebo","volume":"4","author":"Cassano","year":"1994","journal-title":"European Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD010677.pub2-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1192\/bjp.160.2.191","article-title":"Drug treatment of panic disorder: comparative efficacy of alprazolam, imipramine, and placebo","volume":"160","author":"Cross National Collaborative Panic Study Second Phase Investigators","year":"1992","journal-title":"British Journal of Psychiatry"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD010677.pub2-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/0022-3956(93)90023-U","article-title":"Maintenance drug therapy of panic disorder","volume":"27","author":"Curtis","year":"1993","journal-title":"Journal of Psychiatric Research"},{"issue":"3","key":"10.1002\/14651858.CD010677.pub2-BIB0014|cit14","first-page":"121","article-title":"Patients with panic disorder unaccompanied by depression improve with alprazolam and imipramine treatment","volume":"52","author":"Deltito","year":"1991","journal-title":"Journal of Clinical Psychiatry"},{"issue":"365","key":"10.1002\/14651858.CD010677.pub2-BIB0015|cit15","first-page":"5","article-title":"Alprazolam, imipramine and placebo treatment of panic disorder in Scandinavia. A report from the Cross-National Collaborative Panic Study, second phase: Introduction","volume":"83","author":"Just","year":"1991","journal-title":"Acta Psychiatrica Scandinavica, Supplementum"},{"issue":"5","key":"10.1002\/14651858.CD010677.pub2-BIB0017|cit16","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1001\/archpsyc.1988.01800290021003","article-title":"Overview of the Cross-National Collaborative Panic Study","volume":"45","author":"Klerman","year":"1988","journal-title":"Archives of General Psychiatry"},{"issue":"1","key":"10.1002\/14651858.CD010677.pub2-BIB0016|cit17","first-page":"59","article-title":"The design and conduct of the Upjohn Cross-National Collaborative Panic Study","volume":"22","author":"Klerman","year":"1986","journal-title":"Psychopharmacology Bulletin"},{"issue":"1-2","key":"10.1002\/14651858.CD010677.pub2-BIB0018|cit18","first-page":"59","article-title":"Comparison of the effect of alprazolam, imipramine and placebo in the treatment of panic disorders in Cali, Colombia","volume":"36","author":"Leon","year":"1990","journal-title":"Acta Psiquiatrica y Psicologica de America Latina"},{"issue":"1","key":"10.1002\/14651858.CD010677.pub2-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1159\/000257936","article-title":"The relevance of agoraphobic syndromes for diagnosis and drug therapy in patients with panic disorder","volume":"1","author":"Maier","year":"1991","journal-title":"Verhaltenstherapie"},{"issue":"6","key":"10.1002\/14651858.CD010677.pub2-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"374","DOI":"10.3928\/0048-5713-19910601-11","article-title":"Agoraphobia in panic disorder: an indicator of the severity of panic disorder or a distinct diagnostic entity?","volume":"21","author":"Maier","year":"1991","journal-title":"Psychiatric Annals"},{"issue":"3","key":"10.1002\/14651858.CD010677.pub2-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/BF02219714","article-title":"Avoidance behaviour: a predictor of the efficacy of pharmacotherapy in panic disorder?","volume":"241","author":"Maier","year":"1991","journal-title":"European Archives of Psychiatry and Clinical Neuroscience"},{"key":"10.1002\/14651858.CD010677.pub2-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1111\/j.1600-0447.1991.tb03101.x","article-title":"Alprazolam, imipramine and placebo treatment of panic disorder: predicting therapeutic response","volume":"365","author":"Rosenberg","year":"1991","journal-title":"Acta Psychiatrica Scandinavica, Supplementum"},{"key":"10.1002\/14651858.CD010677.pub2-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/j.1600-0447.1991.tb03100.x","article-title":"Secondary depression in panic disorder: an indicator of severity with a weak effect on outcome in alprazolam and imipramine treatment","volume":"365","author":"Rosenberg","year":"1991","journal-title":"Acta Psychiatrica Scandinavica"},{"issue":"1 Pt B","key":"10.1002\/14651858.CD010677.pub2-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1097\/00002826-199202001-01212","article-title":"Discontinuation effects following short-term or long-term treatment of panic disorder with alprazolam and imipramine","volume":"15","author":"Rosenberg","year":"1992","journal-title":"Clinical Neuropharmacology"},{"key":"10.1002\/14651858.CD010677.pub2-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1002\/anxi.3070010205","article-title":"Patient Stage of Change predicts outcome in a panic disorder medication trial","volume":"1","author":"Beitman","year":"1994","journal-title":"Anxiety"},{"issue":"4","key":"10.1002\/14651858.CD010677.pub2-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1097\/00004714-199408000-00005","article-title":"Adinazolam sustained-release treatment of panic disorder: a double-blind study","volume":"14","author":"Davidson","year":"1994","journal-title":"Journal of Clinical Psychopharmacology"},{"issue":"3","key":"10.1002\/14651858.CD010677.pub2-BIB0027|cit27","first-page":"88","article-title":"Relationship of past depressive episodes to symptom severity and treatment response in panic disorder with agoraphobia","volume":"54","author":"Maddock","year":"1993","journal-title":"Journal of Clinical Psychiatry"},{"issue":"5","key":"10.1002\/14651858.CD010677.pub2-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/0887-6185(96)00014-X","article-title":"Effectiveness of stages of change and adinazolam SR in panic disorder: a neural network analysis","volume":"10","author":"Reid","year":"1996","journal-title":"Journal of Anxiety Disorders"},{"issue":"1","key":"10.1002\/14651858.CD010677.pub2-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/0165-1781(89)90171-6","article-title":"The relationship of panic disorder and its treatment outcome to 24-hour urinary MHPG levels","volume":"30","author":"Garvey","year":"1989","journal-title":"Psychiatry Research"},{"key":"10.1002\/14651858.CD010677.pub2-BIB0030|cit30","unstructured":"GlaxoSmithKline A double-blind, multicentered, flexible-dose study of paroxetine, alprazolam and placebo in the treatment of panic disorder www.gsk-clinicalstudyregister.com\/study\/29060\/223#rs"},{"issue":"1","key":"10.1002\/14651858.CD010677.pub2-BIB0032|cit31","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1037\/0022-006X.58.1.77","article-title":"A comparison of alprazolam and behavior therapy in treatment of panic disorder","volume":"58","author":"Klosko","year":"1990","journal-title":"Journal of Consulting and Clinical Psychology"},{"key":"10.1002\/14651858.CD010677.pub2-BIB0031|cit32","first-page":"105-21","article-title":"A comparison of alprazolam and behavior therapy in treatment of panic disorder","volume-title":"The Neurotic Paradox, Volume 1: Progress in Understanding and Treating Anxiety and Related Disorders","author":"Klosko","year":"2016"},{"key":"10.1002\/14651858.CD010677.pub2-BIB0033|cit33","doi-asserted-by":"crossref","DOI":"10.1007\/978-3-642-73543-1_5","article-title":"Comparison of alprazolam and cognitive-behavior therapy in the treatment of panic disorder. A preliminary report","volume-title":"Panic and phobias 2: Treatment and variables affecting course and outcome","author":"Klosko","year":"1988"},{"issue":"11","key":"10.1002\/14651858.CD010677.pub2-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1176\/ajp.149.11.1556","article-title":"Alprazolam plasma concentrations and treatment response in panic disorder and agoraphobia","volume":"149","author":"Lesser","year":"1992","journal-title":"American Journal of Psychiatry"},{"issue":"2","key":"10.1002\/14651858.CD010677.pub2-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1097\/00004714-199204000-00004","article-title":"A fixed-dose study of alprazolam 2 mg, alprazolam 6 mg, and placebo in panic disorder","volume":"12","author":"Lydiard","year":"1992","journal-title":"Journal of Clinical Psychopharmacology"},{"issue":"2","key":"10.1002\/14651858.CD010677.pub2-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1097\/00004714-199104000-00020","article-title":"Effect of alprazolam on depression in panic disorder","volume":"11","author":"Melvin","year":"1991","journal-title":"Journal of Clinical Psychopharmacology"},{"issue":"8","key":"10.1002\/14651858.CD010677.pub2-BIB0037|cit37","first-page":"1187","article-title":"The effects of clonazepam on quality of life and work productivity in panic disorder","volume":"3","author":"Jacobs","year":"1997","journal-title":"American Journal of Managed Care"},{"key":"10.1002\/14651858.CD010677.pub2-BIB0039|cit38","unstructured":"Moroz G Clonazepam efficacy in the treatment of panic disorder - results of a multicenter placebo-controlled trial. 149th Annual Meeting of the American Psychiatric Association; 1996 May 4-9; New York, NY 1996"},{"issue":"9","key":"10.1002\/14651858.CD010677.pub2-BIB0038|cit39","doi-asserted-by":"crossref","first-page":"604","DOI":"10.4088\/JCP.v60n0907","article-title":"Efficacy, safety, and gradual discontinuation of clonazepam in panic disorder: a placebo-controlled, multicenter study using optimized dosages","volume":"60","author":"Moroz","year":"1999","journal-title":"Journal of Clinical Psychiatry"},{"issue":"2","key":"10.1002\/14651858.CD010677.pub2-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1097\/00004714-198904000-00023","article-title":"Actual medication versus therapist guesses: in a blind study, how blind is blind?","volume":"9","author":"Munjack","year":"1989","journal-title":"Journal of Clinical Psychopharmacology"},{"issue":"1","key":"10.1002\/14651858.CD010677.pub2-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1097\/00004714-198902000-00005","article-title":"Alprazolam, propranolol, and placebo in the treatment of panic disorder and agoraphobia with panic attacks","volume":"9","author":"Munjack","year":"1989","journal-title":"Journal of Clinical Psychopharmacology"},{"issue":"1","key":"10.1002\/14651858.CD010677.pub2-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/0306-4530(90)90043-9","article-title":"Reduction in urinary free cortisol during benzodiazepine treatment of panic disorder","volume":"15","author":"Lopez","year":"1990","journal-title":"Psychoneuroendocrinology"},{"issue":"8","key":"10.1002\/14651858.CD010677.pub2-BIB0043|cit43","first-page":"349","article-title":"Diazepam versus alprazolam for the treatment of panic disorder","volume":"57","author":"Noyes","year":"1996","journal-title":"Journal of Clinical Psychiatry"},{"issue":"4","key":"10.1002\/14651858.CD010677.pub2-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1176\/ajp.148.4.517","article-title":"Controlled discontinuation of benzodiazepine treatment for patients with panic disorder","volume":"148","author":"Noyes","year":"1991","journal-title":"American Journal of Psychiatry"},{"issue":"5","key":"10.1002\/14651858.CD010677.pub2-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1097\/00004714-199410000-00005","article-title":"A double-blind, placebo-controlled, multicenter study with alprazolam and extended-release alprazolam in the treatment of panic disorder","volume":"14","author":"Pecknold","year":"1994","journal-title":"Journal of Clinical Psychopharmacology"},{"issue":"4","key":"10.1002\/14651858.CD010677.pub2-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/0022-3956(93)90064-9","article-title":"Panic factor: outcome variable in panic disorder","volume":"27","author":"Pecknold","year":"1993","journal-title":"Journal of Psychiatric Research"},{"issue":"5","key":"10.1002\/14651858.CD010677.pub2-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1097\/00004714-199710000-00008","article-title":"Clonazepam in the treatment of panic disorder with or without agoraphobia: a dose-response study of efficacy, safety, and discontinuance. Clonazepam Panic Disorder Dose-Response Study Group","volume":"17","author":"Rosenbaum","year":"1997","journal-title":"Journal of Clinical Psychopharmacology"},{"issue":"3","key":"10.1002\/14651858.CD010677.pub2-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1185\/03007999009111500","article-title":"Etizolam versus placebo in the treatment of panic disorder with agoraphobia: a double-blind study","volume":"12","author":"Savoldi","year":"1990","journal-title":"Current Medical Research and Opinion"},{"issue":"1","key":"10.1002\/14651858.CD010677.pub2-BIB0049|cit49","first-page":"19","article-title":"The use of low-dose intranasal midazolam to treat panic disorder: a pilot study","volume":"53","author":"Schweizer","year":"1992","journal-title":"Journal of Clinical Psychiatry"},{"issue":"9","key":"10.1002\/14651858.CD010677.pub2-BIB0052|cit50","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1016\/0011-393X(95)85102-X","article-title":"Once-a-day control of panic disorder: evidence from a placebo-controlled trial of alprazolam extended release","volume":"56","author":"Schweizer","year":"1995","journal-title":"Current Therapeutic Research, Clinical & Experimental"},{"issue":"Suppl 1 Pt B","key":"10.1002\/14651858.CD010677.pub2-BIB0050|cit51","doi-asserted-by":"crossref","first-page":"26B","DOI":"10.1097\/00002826-199202001-00049","article-title":"A once-a-day, slow-release form of alprazolam for the treatment of panic disorder: a placebo-controlled study","volume":"15","author":"Schweizer","year":"1992","journal-title":"Clinical Neuropharmacology"},{"issue":"8","key":"10.1002\/14651858.CD010677.pub2-BIB0051|cit52","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1176\/ajp.150.8.1210","article-title":"Double-blind, placebo-controlled study of a once-a-day, sustained-release preparation of alprazolam for the treatment of panic disorder","volume":"150","author":"Schweizer","year":"1993","journal-title":"American Journal of Psychiatry"},{"issue":"6 Suppl 2","key":"10.1002\/14651858.CD010677.pub2-BIB0054|cit53","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1097\/00004714-199812001-00004","article-title":"Panic disorder: long-term pharmacotherapy and discontinuation","volume":"18","author":"Rickels","year":"1998","journal-title":"Journal of Clinical Psychopharmacology"},{"issue":"1","key":"10.1002\/14651858.CD010677.pub2-BIB0053|cit54","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1001\/archpsyc.1993.01820130067010","article-title":"Maintenance drug treatment for panic disorder. II. Short- and long-term outcome after drug taper","volume":"50","author":"Rickels","year":"1993","journal-title":"Archives of General Psychiatry"},{"issue":"1","key":"10.1002\/14651858.CD010677.pub2-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1001\/archpsyc.1993.01820130053009","article-title":"Maintenance drug treatment of panic disorder. I. Results of a prospective, placebo-controlled comparison of alprazolam and imipramine","volume":"50","author":"Schweizer","year":"1993","journal-title":"Archives of General Psychiatry"},{"issue":"1","key":"10.1002\/14651858.CD010677.pub2-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1600-0447.1993.tb03405.x","article-title":"The relative efficacy of high-dose buspirone and alprazolam in the treatment of panic disorder: a double-blind placebo-controlled study","volume":"88","author":"Sheehan","year":"1993","journal-title":"Acta Psychiatrica Scandinavica"},{"issue":"1","key":"10.1002\/14651858.CD010677.pub2-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"107","DOI":"10.2190\/KQEJ-MQJR-VK3D-F3HV","article-title":"Treatment of panic disorder in older adults: a pilot study comparison of alprazolam, imipramine, and placebo","volume":"29","author":"Sheikh","year":"1999","journal-title":"International Journal of Psychiatry in Medicine"},{"issue":"4","key":"10.1002\/14651858.CD010677.pub2-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1176\/ajp.147.4.507","article-title":"Surreptitious drug use by patients in a panic disorder study","volume":"147","author":"Clark","year":"1990","journal-title":"American Journal of Psychiatry"},{"issue":"1","key":"10.1002\/14651858.CD010677.pub2-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1037\/0022-006X.59.1.184","article-title":"How \"blind\" are double-blind studies?","volume":"59","author":"Margraf","year":"1991","journal-title":"Journal of Consulting and Clinical Psychology"},{"issue":"2","key":"10.1002\/14651858.CD010677.pub2-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1097\/00004714-199004000-00006","article-title":"Cardiovascular and symptomatic reduction effects of alprazolam and imipramine in patients with panic disorder: results of a double-blind, placebo-controlled trial","volume":"10","author":"Taylor","year":"1990","journal-title":"Journal of Clinical Psychopharmacology"},{"issue":"4","key":"10.1002\/14651858.CD010677.pub2-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1097\/00004714-199308000-00005","article-title":"Long-term outcome after acute treatment with alprazolam or clonazepam for panic disorder","volume":"13","author":"Pollack","year":"1993","journal-title":"Journal of Clinical Psychopharmacology"},{"issue":"Suppl","key":"10.1002\/14651858.CD010677.pub2-BIB0062|cit62","first-page":"16","article-title":"Clonazepam versus alprazolam in the treatment of panic disorder: interim analysis of data from a prospective, double-blind, placebo-controlled trial","volume":"48","author":"Tesar","year":"1987","journal-title":"Journal of Clinical Psychiatry"},{"issue":"2","key":"10.1002\/14651858.CD010677.pub2-BIB0063|cit63","first-page":"69","article-title":"Double-blind, placebo-controlled comparison of clonazepam and alprazolam for panic disorder","volume":"52","author":"Tesar","year":"1991","journal-title":"Journal of Clinical Psychiatry"},{"issue":"3","key":"10.1002\/14651858.CD010677.pub2-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/0165-0327(89)90009-8","article-title":"Response of panic disorder to fixed doses of alprazolam or imipramine","volume":"17","author":"Uhlenhuth","year":"1989","journal-title":"Journal of Affective Disorders"},{"issue":"4","key":"10.1002\/14651858.CD010677.pub2-BIB0065|cit65","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1590\/S0004-282X2000000600008","article-title":"Double-blind clonazepam vs placebo in panic disorder treatment","volume":"58","author":"Valenca","year":"2000","journal-title":"Arquivos de Neuro-Psiquiatria"},{"issue":"1","key":"10.1002\/14651858.CD010677.pub2-BIB0066|cit66","first-page":"119","article-title":"Clobazam in the treatment of anxiety neurosis: a double-blind study","volume":"26","author":"Ananth","year":"1979","journal-title":"Current Therapeutic Research, Clinical and Experimental"},{"issue":"5","key":"10.1002\/14651858.CD010677.pub2-BIB0067|cit67","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1001\/archpsyc.1988.01800290027004","article-title":"Alprazolam in panic disorder and agoraphobia: results from a multicenter trial. I. Efficacy in short-term treatment","volume":"45","author":"Ballenger","year":"1988","journal-title":"Archives of General Psychiatry"},{"issue":"9","key":"10.1002\/14651858.CD010677.pub2-BIB0068|cit68","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1001\/archpsyc.1993.01820210049006","article-title":"Plasma alprazolam concentrations. Relation to efficacy and side effects in the treatment of panic disorder","volume":"50","author":"Greenblatt","year":"1993","journal-title":"Archives of General Psychiatry"},{"issue":"5","key":"10.1002\/14651858.CD010677.pub2-BIB0069|cit69","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1001\/archpsyc.1988.01800290037005","article-title":"Alprazolam in panic disorder and agoraphobia: results from a multicenter trial. II. Patient acceptance, side effects, and safety","volume":"45","author":"Noyes","year":"1988","journal-title":"Archives of General Psychiatry"},{"issue":"1","key":"10.1002\/14651858.CD010677.pub2-BIB0071|cit70","first-page":"173","article-title":"Taper withdrawal studies with alprazolam in patients with panic disorder and agoraphobia","volume":"22","author":"Pecknold","year":"1986","journal-title":"Psychopharmacology Bulletin"},{"issue":"5","key":"10.1002\/14651858.CD010677.pub2-BIB0070|cit71","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1001\/archpsyc.1988.01800290043006","article-title":"Alprazolam in panic disorder and agoraphobia: results from a multicenter trial. III. Discontinuation effects","volume":"45","author":"Pecknold","year":"1988","journal-title":"Archives of General Psychiatry"},{"issue":"1","key":"10.1002\/14651858.CD010677.pub2-BIB0072|cit72","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0022-3956(90)90020-Q","article-title":"Sequence of improvement in agoraphobia with panic attacks","volume":"24","author":"Rifkin","year":"1990","journal-title":"Journal of Psychiatric Research"},{"issue":"2-3","key":"10.1002\/14651858.CD010677.pub2-BIB0073|cit73","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/0278-5846(87)90047-9","article-title":"Psychopharmacological treatment of panic disorder and related states: a placebo controlled study of alprazolam","volume":"11","author":"Swinson","year":"1987","journal-title":"Progress in Neuro-Psychopharmacology and Biological Psychiatry"},{"issue":"1","key":"10.1002\/14651858.CD010677.pub2-BIB0074|cit74","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/0165-0327(94)90146-5","article-title":"Predictors of response to alprazolam and placebo in patients with panic disorder","volume":"30","author":"Woodman","year":"1994","journal-title":"Journal of Affective Disorders"},{"issue":"5","key":"10.1002\/14651858.CD010677.pub2-BIB0075|cit75","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/0278-5846(91)90049-7","article-title":"The changes of thyroid hormone during pharmacological treatment of panic disorder patients","volume":"15","author":"Balon","year":"1991","journal-title":"Progress in Neuro-Psychopharmacology and Biological Psychiatry"},{"key":"10.1002\/14651858.CD010677.pub2-BIB0076|cit76","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1177\/070674379303800106","article-title":"Changes in appetite and weight during the pharmacological treatment of patients with panic disorder","volume":"38","author":"Balon","year":"1993","journal-title":"Canadian Journal of Psychiatry\/Revue Canadienne de Psychiatrie"},{"key":"10.1002\/14651858.CD010677.pub2-BIB0077|cit77","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1159\/000118801","article-title":"Imipramine-induced jitteriness and decreased serum iron levels","volume":"25","author":"Yeragani","year":"1992","journal-title":"Neuropsychobiology"},{"issue":"4","key":"10.1002\/14651858.CD010677.pub2-BIB0078|cit78","first-page":"285","article-title":"Treatment of neurotic anxiety with clobazam: double-blind clinical trial against placebo","volume":"9","author":"Barbosa","year":"1980","journal-title":"Clinica Terapeutica"},{"issue":"4","key":"10.1002\/14651858.CD010677.pub2-BIB0079|cit79","first-page":"203","article-title":"Double-blind comparative study of alprazolam (Xanax) and amitriptyline in the treatment of anxiety associated with depression","volume":"29","author":"Bernardi","year":"1988","journal-title":"Minerva Psichiatrica"},{"issue":"2","key":"10.1002\/14651858.CD010677.pub2-BIB0080|cit80","first-page":"97","article-title":"Anti anxiety activity of buspirone: comparative trial with placebo and diazepam","volume":"37","author":"Bueno","year":"1988","journal-title":"Jornal Brasileiro de Psiquiatria"},{"issue":"3","key":"10.1002\/14651858.CD010677.pub2-BIB0081|cit81","first-page":"146","article-title":"Buspirone vs diazepam treatment of anxiety disorders in a double blind study","volume":"3","author":"Chen","year":"1997","journal-title":"Zhongyuan Journal of Psychologic Medicine"},{"issue":"2","key":"10.1002\/14651858.CD010677.pub2-BIB0082|cit82","first-page":"99","article-title":"Buspirone vs diazepam in treating anxiety disorders in a double-blind study","volume":"17","author":"Chen","year":"1998","journal-title":"Chinese Journal of New Drugs and Clinical Remedies"},{"issue":"7","key":"10.1002\/14651858.CD010677.pub2-BIB0083|cit83","first-page":"405","article-title":"Mianserin vs. alprazolam in treating anxiety disorder","volume":"22","author":"Chen","year":"2003","journal-title":"Chinese Journal of New Drugs and Clinical Remedies"},{"issue":"3","key":"10.1002\/14651858.CD010677.pub2-BIB0084|cit84","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/BF00464571","article-title":"Alprazolam in the treatment of generalized anxiety and panic disorders: a double-blind placebo-controlled study","volume":"77","author":"Chouinard","year":"1982","journal-title":"Psychopharmacology"},{"issue":"1","key":"10.1002\/14651858.CD010677.pub2-BIB0085|cit85","first-page":"115","article-title":"Alprazolam in the treatment of generalized anxiety and panic disorders: a double-blind placebo-controlled study","volume":"18","author":"Chouinard","year":"1983","journal-title":"Psychopharmacology Bulletin"},{"issue":"2","key":"10.1002\/14651858.CD010677.pub2-BIB0086|cit86","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1002\/j.1875-9114.1984.tb03327.x","article-title":"Long-term comparison of alprazolam, lorazepam and placebo in patients with an anxiety disorder","volume":"4","author":"Cohn","year":"1984","journal-title":"Pharmacotherapy"},{"issue":"1","key":"10.1002\/14651858.CD010677.pub2-BIB0087|cit87","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/0924-977X(90)90016-4","article-title":"Beta 2-adrenoceptor antagonism in anxiety","volume":"1","author":"Cooper","year":"1990","journal-title":"European Neuropsychopharmacology"},{"issue":"2","key":"10.1002\/14651858.CD010677.pub2-BIB0088|cit88","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1177\/026988119100500210","article-title":"A comparison of beta-2-adrenoceptor antagonist (ICI 118,551), diazepam and placebo in the treatment of acute anxiety","volume":"5","author":"Cooper","year":"1991","journal-title":"Journal of Psychopharmacology"},{"issue":"1","key":"10.1002\/14651858.CD010677.pub2-BIB0089|cit89","first-page":"166","article-title":"Triflubazam (ORF 8063), a new benzodiazepine in anxiety neurosis","volume":"22","author":"Csanalosi","year":"1977","journal-title":"Current Therapeutic Research, Clinical and Experimental"},{"issue":"1","key":"10.1002\/14651858.CD010677.pub2-BIB0090|cit90","first-page":"27","article-title":"Anti-anxiety activity of cannabidiol; double-blind, comparative trial with diazepam and placebo","volume":"4","author":"Cunha","year":"1988","journal-title":"R. Cent. Ci.c Biom\u00e9d. Univ. Fed. Uberl\u00e2ndia"},{"issue":"4","key":"10.1002\/14651858.CD010677.pub2-BIB0091|cit91","doi-asserted-by":"crossref","first-page":"251","DOI":"10.3109\/10401239209150457","article-title":"Long-term outcome of panic states during double-blind treatment and after withdrawal of alprazolam and placebo","volume":"4","author":"Dager","year":"1992","journal-title":"Annals of Clinical Psychiatry"},{"issue":"2","key":"10.1002\/14651858.CD010677.pub2-BIB0092|cit92","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1159\/000286683","article-title":"The effect of daily oral dosage of diazepam, plasma concentrations and metabolic clearance of diazepam and demethyldiazepam on various constituents of the acute clinical anxiety syndrome","volume":"24","author":"Dasberg","year":"1974","journal-title":"Psychotherapy and Psychosomatics"},{"issue":"11 Pt 2","key":"10.1002\/14651858.CD010677.pub2-BIB0093|cit93","first-page":"4","article-title":"Anxiety: differential diagnosis and treatment from a biologic perspective","volume":"42","author":"Davis","year":"1981","journal-title":"Journal of Clinical Psychiatry"},{"issue":"12","key":"10.1002\/14651858.CD010677.pub2-BIB0094|cit94","doi-asserted-by":"crossref","first-page":"2851","DOI":"10.1016\/j.clinthera.2009.12.010","article-title":"Effects of treatment with etizolam 0.5 mg BID on cognitive performance: a 3-week, multicenter, randomized, double-blind, placebo-controlled, two-treatment, three-period, noninferiority crossover study in patients with anxiety disorder","volume":"31","author":"Candia","year":"2009","journal-title":"Clinical Therapeutics"},{"issue":"6","key":"10.1002\/14651858.CD010677.pub2-BIB0095|cit95","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1055\/s-2007-1014613","article-title":"A comparative study of suriclone, lorazepam and placebo in anxiety disorder","volume":"22","author":"Jonghe","year":"1989","journal-title":"Pharmacopsychiatry"},{"issue":"2","key":"10.1002\/14651858.CD010677.pub2-BIB0096|cit96","first-page":"127","article-title":"Randomized double-blind study of loxapine as compared with diazepam in therapy of patients with anxiety neuroses","volume":"95","author":"Rosa","year":"1980","journal-title":"Clinica Terapeutica"},{"issue":"5","key":"10.1002\/14651858.CD010677.pub2-BIB0097|cit97","first-page":"3","article-title":"Treatment of autonomic crises (attacks of panic)","volume":"91","author":"Diukova","year":"1991","journal-title":"Zhurnal Nevropatologii i Psikhiatrii Imeni S. S. Korsakova"},{"issue":"1","key":"10.1002\/14651858.CD010677.pub2-BIB0098|cit98","first-page":"22","article-title":"Treatment of autonomic attacks (panic attacks)","volume":"26","author":"Diukova","year":"1993","journal-title":"Journal of Russian and East European Psychiatry"},{"issue":"5","key":"10.1002\/14651858.CD010677.pub2-BIB0099|cit99","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1055\/s-0028-1094580","article-title":"Prediction of response to chlordiazepoxide and placebo in anxious outpatients: an attempt at replication","volume":"11","author":"Downing","year":"1978","journal-title":"Pharmakopsychiatr Neuropsychopharmakol"},{"issue":"5","key":"10.1002\/14651858.CD010677.pub2-BIB0100|cit100","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1111\/j.1600-0447.1979.tb00554.x","article-title":"Nonspecific factors and side effect complaints. Factors affecting the incidence of drowsiness in drug and placebo treated anxious and depressed outpatients","volume":"60","author":"Downing","year":"1979","journal-title":"Acta Psychiatrica Scandinavica"},{"issue":"3","key":"10.1002\/14651858.CD010677.pub2-BIB0101|cit101","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1097\/00005053-198303000-00009","article-title":"Physician prognosis in relationship to drug and placebo response in anxious and depressed psychiatric outpatients","volume":"171","author":"Downing","year":"1983","journal-title":"Journal of Nervous and Mental Disease"},{"issue":"9","key":"10.1002\/14651858.CD010677.pub2-BIB0102|cit102","first-page":"458","article-title":"Effect of alprazolam and diazepam on anxiety and panic attacks in panic disorder: a controlled study","volume":"47","author":"Dunner","year":"1986","journal-title":"Journal of Clinical Psychiatry"},{"issue":"7","key":"10.1002\/14651858.CD010677.pub2-BIB0103|cit103","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1176\/ajp.146.7.860","article-title":"Relapse and rebound following discontinuation of benzodiazepine treatment of panic attacks: alprazolam versus diazepam","volume":"146","author":"Roy-Byrne","year":"1989","journal-title":"American Journal of Psychiatry"},{"issue":"3","key":"10.1002\/14651858.CD010677.pub2-BIB0104|cit104","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/0165-1781(89)90215-1","article-title":"Dehydroepiandrosterone-sulfate\/cortisol ratio in panic disorder","volume":"28","author":"Fava","year":"1989","journal-title":"Psychiatry Research"},{"issue":"C","key":"10.1002\/14651858.CD010677.pub2-BIB0105|cit105","first-page":"27","article-title":"A double-blind, placebo-controlled study with tofizopam in anxiety neurosis","volume":"22","author":"Filip","year":"1981","journal-title":"Agressologie"},{"issue":"2","key":"10.1002\/14651858.CD010677.pub2-BIB0106|cit106","first-page":"101-10","article-title":"Clomipramine and diazepam plasma levels in panic disorder and agoraphobia: preliminary findings","volume":"27","author":"Franulic","year":"1989","journal-title":"Revista Chilena de Neuro-psiquiatria"},{"key":"10.1002\/14651858.CD010677.pub2-BIB0107|cit107","unstructured":"Gloger KS Gladic MD O'Ryan GF Barahona CM Clomipramine and diazepam in the treatment of panic anxiety: a double-blind comparison study Unpublished"},{"issue":"11-12","key":"10.1002\/14651858.CD010677.pub2-BIB0108|cit108","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1002\/j.1552-4604.1980.tb01689.x","article-title":"Double-blind clinical assessment of alprazolam, a new benzodiazepine derivative, in the treatment of moderate to severe anxiety","volume":"20","author":"Greiss","year":"1980","journal-title":"Journal of Clinical Pharmacology"},{"issue":"1","key":"10.1002\/14651858.CD010677.pub2-BIB0109|cit109","first-page":"39","article-title":"Treatment of anxiety and depression: a comparative trial of amitriptyline (Laroxyl) and diazepam (Valium)","volume":"11","author":"Hare","year":"1974","journal-title":"Clinical Trials Journal"},{"issue":"5","key":"10.1002\/14651858.CD010677.pub2-BIB0110|cit110","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1097\/JCP.0000000000000757","article-title":"No effects of d-cycloserine enhancement in exposure with response prevention therapy in panic disorder with agoraphobia: a double-blind, randomized controlled trial","volume":"37","author":"Hofmeijer-Sevink","year":"2017","journal-title":"Journal of Clinical Psychopharmacology"},{"issue":"2","key":"10.1002\/14651858.CD010677.pub2-BIB0111|cit111","first-page":"85","article-title":"A comparative study in psychotherapy and drug in treatment of anxiety disorders","volume":"28","author":"Hu","year":"2002","journal-title":"Chinese Journal of Nervous and Mental Diseases"},{"issue":"8","key":"10.1002\/14651858.CD010677.pub2-BIB0112|cit112","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1176\/appi.ajp.161.8.1485","article-title":"Differential response to placebo among patients with social phobia, panic disorder, and obsessive-compulsive disorder","volume":"161","author":"Huppert","year":"2004","journal-title":"American Journal of Psychiatry"},{"issue":"1","key":"10.1002\/14651858.CD010677.pub2-BIB0113|cit113","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1001\/archpsyc.1986.01800010081010","article-title":"Imipramine and chlordiazepoxide in depressive and anxiety disorders. II. Efficacy in anxious outpatients","volume":"43","author":"Kahn","year":"1986","journal-title":"Archives of General Psychiatry"},{"issue":"3","key":"10.1002\/14651858.CD010677.pub2-BIB0114|cit114","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1097\/00004714-200006000-00008","article-title":"Differences in pharmacodynamics but not pharmacokinetics between subjects with panic disorder and healthy subjects after treatment with a single dose of alprazolam","volume":"20","author":"Kaplan","year":"2000","journal-title":"Journal of Clinical Psychopharmacology"},{"issue":"1","key":"10.1002\/14651858.CD010677.pub2-BIB0115|cit115","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/0165-0327(93)90074-T","article-title":"Influence of depression on the treatment of panic disorder with imipramine, alprazolam and placebo","volume":"28","author":"Keller","year":"1993","journal-title":"Journal of Affective Disorders"},{"issue":"2","key":"10.1002\/14651858.CD010677.pub2-BIB0116|cit116","first-page":"163","article-title":"Effect size as a measure of symptom-specific drug change in clinical trials","volume":"29","author":"Leon","year":"1993","journal-title":"Psychopharmacology Bulletin"},{"issue":"4","key":"10.1002\/14651858.CD010677.pub2-BIB0117|cit117","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/0165-0327(94)90134-1","article-title":"Anxiety psychopathology predictive of outcome in patients with panic disorder and depression treated with imipramine, alprazolam and placebo","volume":"30","author":"Pollack","year":"1994","journal-title":"Journal of Affective Disorders"},{"issue":"2","key":"10.1002\/14651858.CD010677.pub2-BIB0118|cit118","first-page":"273","article-title":"Pattern of placebo response in panic disorder","volume":"31","author":"Shear","year":"1995","journal-title":"Psychopharmacology Bulletin"},{"issue":"7","key":"10.1002\/14651858.CD010677.pub2-BIB0119|cit119","first-page":"451","article-title":"Alprazolam in the treatment of neurotic anxiety","volume":"3","author":"Kerry","year":"1983","journal-title":"Pharmatherapeutica"},{"issue":"8618","key":"10.1002\/14651858.CD010677.pub2-BIB0120|cit120","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1016\/S0140-6736(88)90760-X","article-title":"Nottingham study of neurotic disorder","volume":"2","author":"Klein","year":"1988","journal-title":"Lancet"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD010677.pub2-BIB0121|cit121","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/0022-3956(90)90033-M","article-title":"Depression and panic anxiety: the effect of depressive co-morbidity on response to drug treatment of patients with panic disorder and agoraphobia","volume":"24","author":"Klerman","year":"1990","journal-title":"Journal of Psychiatric Research"},{"issue":"4","key":"10.1002\/14651858.CD010677.pub2-BIB0122|cit122","first-page":"209","article-title":"Comparative study of cloxazolam and placebo in anxiety neurosis","volume":"39","author":"Knijnik","year":"1990","journal-title":"Jornal Brasileiro de Psiquiatria"},{"issue":"8","key":"10.1002\/14651858.CD010677.pub2-BIB0123|cit123","first-page":"1233","article-title":"Double blind study with the benzodiazepine derivative Ka-2547 in outpatients with anxiety neurosis","volume":"30","author":"Laakmann","year":"1980","journal-title":"Arzneimittelforschung"},{"issue":"4","key":"10.1002\/14651858.CD010677.pub2-BIB0124|cit124","first-page":"315","article-title":"Clinical and physiological assessment of chlorazepate, diazepam and placebo in anxious neurotics","volume":"11","author":"Lapierre","year":"1975","journal-title":"International Journal of Clinical Pharmacology and Biopharmacy"},{"key":"10.1002\/14651858.CD010677.pub2-BIB0125|cit125","first-page":"199","article-title":"Treatment of panic disorder: pharmacological versus behavioral therapy?","volume":"28","author":"Lorch","year":"1995","journal-title":"Pharmacopsychiatry"},{"issue":"3","key":"10.1002\/14651858.CD010677.pub2-BIB0126|cit126","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/0165-0327(95)00053-4","article-title":"Behavioural aggression in panic disorder after 8 weeks' treatment with alprazolam","volume":"35","author":"Bond","year":"1995","journal-title":"Journal of Affective Disorders"},{"issue":"4","key":"10.1002\/14651858.CD010677.pub2-BIB0127|cit127","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1017\/S0033291700029056","article-title":"Memory functions, alprazolam and exposure therapy: a controlled longitudinal study of agoraphobia with panic disorder","volume":"24","author":"Curran","year":"1994","journal-title":"Psychological Medicine"},{"key":"10.1002\/14651858.CD010677.pub2-BIB0128|cit128","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1192\/bjp.162.6.776","article-title":"Alprazolam and exposure alone and combined in panic disorder with agoraphobia. A controlled study in London and Toronto","volume":"162","author":"Marks","year":"1993","journal-title":"British Journal of Psychiatry"},{"issue":"2","key":"10.1002\/14651858.CD010677.pub2-BIB0129|cit129","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1192\/bjp.165.1.79","article-title":"Safety and side-effects of alprazolam. Controlled study in agoraphobia with panic disorder","volume":"165","author":"O'Sullivan","year":"1994","journal-title":"British Journal of Psychiatry"},{"issue":"2","key":"10.1002\/14651858.CD010677.pub2-BIB0130|cit130","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1177\/026988119601000204","article-title":"Alprazolam withdrawal symptoms in agoraphobia with panic disorder: observations from a controlled Anglo-Canadian study","volume":"10","author":"O'Sullivan","year":"1996","journal-title":"Journal of Psychopharmacology"},{"issue":"4","key":"10.1002\/14651858.CD010677.pub2-BIB0131|cit131","first-page":"91","article-title":"Agoraphobia: behavioral and pharmacological treatments, preliminary outcome, and process findings","volume":"18","author":"Mavissakalian","year":"1982","journal-title":"Psychopharmacology Bulletin"},{"issue":"2","key":"10.1002\/14651858.CD010677.pub2-BIB0132|cit132","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1037\/0022-006X.53.2.229","article-title":"Psychophysiological outcome of behavioral and pharmacological treatments of agoraphobia","volume":"53","author":"Michelson","year":"1985","journal-title":"Journal of Consulting and Clinical Psychology"},{"issue":"10 Pt 2","key":"10.1002\/14651858.CD010677.pub2-BIB0133|cit133","first-page":"30","article-title":"Studies with oral lorazepam in anxiety neurosis associated with depressive symptomatology","volume":"39","author":"McCurdy","year":"1978","journal-title":"Journal of Clinical Psychiatry"},{"issue":"2","key":"10.1002\/14651858.CD010677.pub2-BIB0134|cit134","first-page":"202","article-title":"Double-blind comparison in parallel groups with nightly single doses of halazepam and placebo","volume":"8","author":"McEvilly","year":"1981","journal-title":"Invest med int"},{"issue":"11","key":"10.1002\/14651858.CD010677.pub2-BIB0135|cit135","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1176\/ajp.143.11.1464","article-title":"Withdrawal syndrome with gradual tapering of alprazolam","volume":"143","author":"Mellman","year":"1986","journal-title":"American Journal of Psychiatry"},{"issue":"1 Pt B","key":"10.1002\/14651858.CD010677.pub2-BIB0136|cit136","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1097\/00002826-199202001-01046","article-title":"Combination of alprazolam, antidepressive drugs and cognitive behavior therapy in the treatment of panic disorder","volume":"15","author":"Miretzky","year":"1992","journal-title":"Clinical Neuropharmacology"},{"key":"10.1002\/14651858.CD010677.pub2-BIB0137|cit137","first-page":"261","article-title":"Treatment outcomes of diazepam and oxprenolol with anxiety neurosis patients","volume-title":"Angst und Psychopharmaka: Methoden und Ergebnisse pharmakopsychologischer, pharmakopsychiatrischer und verhaltenspharmakologischer Forschung","author":"Mueller","year":"1986"},{"issue":"12-B Pt 1","key":"10.1002\/14651858.CD010677.pub2-BIB0138|cit138","first-page":"6115","article-title":"Panic: a comparison of four treatment methods","volume":"51","author":"Muncy","year":"1991","journal-title":"Dissertation Abstracts International"},{"issue":"5","key":"10.1002\/14651858.CD010677.pub2-BIB0139|cit139","first-page":"679","article-title":"Ketazolam in the treatment of anxiety: a standard and placebo controlled study","volume":"31","author":"Nair","year":"1982","journal-title":"Current Therapeutic Research, Clinical and Experimental"},{"issue":"7","key":"10.1002\/14651858.CD010677.pub2-BIB0140|cit140","first-page":"500","article-title":"A multicenter investigation of lorazepam in anxiety neurosis","volume":"15","author":"Nanivadekar","year":"1973","journal-title":"Current Therapeutic Research, Clinical and Experimental"},{"issue":"5860","key":"10.1002\/14651858.CD010677.pub2-BIB0141|cit141","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1136\/bmj.2.5860.202","article-title":"Two anti-anxiety drugs: a psychoneuroendocrine study","volume":"2","author":"Ogunremi","year":"1973","journal-title":"British Medical Journal"},{"issue":"16","key":"10.1002\/14651858.CD010677.pub2-BIB0142|cit142","first-page":"494","article-title":"Comparative clinical evaluation of lorazepam","volume":"63","author":"Padron","year":"1974","journal-title":"Schweizerische Rundschau fur Medizin Praxis"},{"issue":"6","key":"10.1002\/14651858.CD010677.pub2-BIB0143|cit143","first-page":"456","article-title":"Double blind study on the use of medazepam in ambulatory therapy]","volume":"13","author":"Pasini","year":"1972","journal-title":"Cahiers de M\u00e9decine (Europa Medica)"},{"issue":"3","key":"10.1002\/14651858.CD010677.pub2-BIB0144|cit144","first-page":"189","article-title":"Efficacy of cloxazolam versus placebo in the therapy of anxious status: double-blind controlled study","volume":"36","author":"Piedade","year":"1987","journal-title":"Jornal Brasileiro de Psiquiatria"},{"issue":"11","key":"10.1002\/14651858.CD010677.pub2-BIB0145|cit145","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1001\/archpsyc.55.11.1010","article-title":"Sertraline in the treatment of panic disorder: A flexible-dose multicenter trial","volume":"55","author":"Pollack","year":"1998","journal-title":"Archives of General Psychiatry"},{"issue":"4","key":"10.1002\/14651858.CD010677.pub2-BIB0146|cit146","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0022-3956(02)00010-9","article-title":"Early improvement predicts endpoint remission status in sertraline and placebo treatments of panic disorder","volume":"36","author":"Pollack","year":"2002","journal-title":"Journal of Psychiatric Research"},{"key":"10.1002\/14651858.CD010677.pub2-BIB0148|cit147","doi-asserted-by":"crossref","unstructured":"Pols H Alprazolam premedication and 35% CO2 vulnerability in panic patients 8th Congress of the Association of European Psychiatrists London, UK 1996","DOI":"10.1016\/0924-9338(96)89201-7"},{"issue":"9","key":"10.1002\/14651858.CD010677.pub2-BIB0147|cit148","doi-asserted-by":"crossref","first-page":"913-7","DOI":"10.1016\/0006-3223(95)00494-7","article-title":"Alprazolam premedication and 35% carbon dioxide vulnerability in panic patients","volume":"40","author":"Pols","year":"1996","journal-title":"Biological Psychiatry"},{"issue":"11","key":"10.1002\/14651858.CD010677.pub2-BIB0149|cit149","first-page":"655","article-title":"Comparative double-blind clinical trial of SB 5833 and temazapam","volume":"54","author":"Porta","year":"1974","journal-title":"Bruxelles Medical"},{"issue":"2","key":"10.1002\/14651858.CD010677.pub2-BIB0150|cit150","first-page":"153","article-title":"The \"double-blind\" procedure in study of the anxiolytic effects of the preparation Wy 3498 (Oxazepam). Evaluation of anxiety states with the Hamilton scale (HS)","volume":"14","author":"Predescu","year":"1969","journal-title":"Neurologia, Psihiatria, Neurochirurgia"},{"issue":"Suppl 8","key":"10.1002\/14651858.CD010677.pub2-BIB0151|cit151","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/S0167-4943(02)00111-5","article-title":"Therapy of panic attacks in the elderly","volume":"35","author":"Raffaele","year":"2002","journal-title":"Archives of Gerontology and Geriatrics"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD010677.pub2-BIB0152|cit152","first-page":"272","article-title":"Alprazolam-XR and neuropsychological function in panic disorder","volume":"3","author":"Rapaport","year":"2000","journal-title":"International Journal of Neuropsychopharmacology"},{"issue":"6","key":"10.1002\/14651858.CD010677.pub2-BIB0153|cit153","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/0010-440X(91)90035-B","article-title":"The sequence of improvement of the symptoms encountered in patients with panic disorder","volume":"32","author":"Rifkin","year":"1991","journal-title":"Comprehensive Psychiatry"},{"issue":"1","key":"10.1002\/14651858.CD010677.pub2-BIB0154|cit154","first-page":"167","article-title":"A comparison of alprazolam and imipramine in the treatment of agoraphobia and panic disorder","volume":"22","author":"Rizley","year":"1986","journal-title":"Psychopharmacology Bulletin"},{"issue":"5","key":"10.1002\/14651858.CD010677.pub2-BIB0155|cit155","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1097\/01.jcp.0000088907.24613.3f","article-title":"Imipramine and buspirone in patients with panic disorder who are discontinuing long-term benzodiazepine therapy","volume":"23","author":"Rynn","year":"2003","journal-title":"Journal of Clinical Psychopharmacology"},{"issue":"1 Pt B","key":"10.1002\/14651858.CD010677.pub2-BIB0156|cit156","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1097\/00002826-199202001-01039","article-title":"Personality traits and treatment response in panic disorder","volume":"15","author":"Saiz-Ruiz","year":"1992","journal-title":"Clinical Neuropharmacology"},{"key":"10.1002\/14651858.CD010677.pub2-BIB0157|cit157","first-page":"531","article-title":"The intravenous infusion use of chlordemethyldiazepam in neurotic anxiety","volume":"3","author":"Scieghi","year":"1986","journal-title":"Rivista Sperimentale Freniatria"},{"issue":"4","key":"10.1002\/14651858.CD010677.pub2-BIB0158|cit158","first-page":"176","article-title":"A placebo-controlled clinical trial with tofizopam in the treament of anxiety neurosis","volume":"27","author":"Sladka","year":"1979","journal-title":"Therapia Hungarica"},{"issue":"4","key":"10.1002\/14651858.CD010677.pub2-BIB0159|cit159","first-page":"178","article-title":"Placebo controlled clinical trial of tofisopam in treatment of anxiety neurosis","volume":"27","author":"Sladka","year":"1979","journal-title":"Therapia Hungarica"},{"issue":"23","key":"10.1002\/14651858.CD010677.pub2-BIB0160|cit160","first-page":"1392","article-title":"Alprazolam (Tafil) and bromazepam (Lexotan) in the treatment of anxiety: a randomized, double-blind comparison in psychiatric outpatients","volume":"148","author":"Sonne","year":"1986","journal-title":"Ugeskrift for Laeger"},{"issue":"10","key":"10.1002\/14651858.CD010677.pub2-BIB0161|cit161","first-page":"423","article-title":"A controlled comparison of relaxation and diazepam in panic disorder","volume":"43","author":"Taylor","year":"1982","journal-title":"Journal of Clinical Psychiatry"},{"issue":"3","key":"10.1002\/14651858.CD010677.pub2-BIB0162|cit162","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/0005-7967(85)90011-7","article-title":"Combined pharmacological and behavioral treatment for agoraphobia","volume":"23","author":"Telch","year":"1985","journal-title":"Behaviour Research and Therapy"},{"issue":"3","key":"10.1002\/14651858.CD010677.pub2-BIB0163|cit163","first-page":"237","article-title":"Evaluation of the anti-anxiety activity of lorazepam in ambulatory patients","volume":"20","author":"Terra","year":"1971","journal-title":"Jornal Brasileiro de Psiquiatria"},{"issue":"5 Suppl","key":"10.1002\/14651858.CD010677.pub2-BIB0164|cit164","first-page":"4","article-title":"High-potency benzodiazepines for short-term management of panic disorder: the US experience","volume":"51","author":"Tesar","year":"1990","journal-title":"Journal of Clinical Psychiatry"},{"issue":"1","key":"10.1002\/14651858.CD010677.pub2-BIB0165|cit165","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/0022-3956(84)90048-7","article-title":"Anxiety in primary care: is short-term drug treatment appropriate?","volume":"18","author":"Tyrer","year":"1984","journal-title":"Journal of Psychiatric Research"},{"issue":"2","key":"10.1002\/14651858.CD010677.pub2-BIB0166|cit166","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1097\/00005053-199602000-00015","article-title":"Long-term benzodiazepine use is associated with smaller treatment gain in panic disorder with agoraphobia","volume":"184","author":"Balkom","year":"1996","journal-title":"Journal of Nervous and Mental Disease"},{"issue":"7","key":"10.1002\/14651858.CD010677.pub2-BIB0167|cit167","first-page":"315","article-title":"First-line treatment of anxiety disorders: a randomized controlled trial","volume":"50","author":"Boeijen","year":"2007","journal-title":"Huisarts en Wetenschap"},{"issue":"1","key":"10.1002\/14651858.CD010677.pub2-BIB0168|cit168","first-page":"27","article-title":"Evaluation of the use of cloxazolam in patients with moderate anxiety","volume":"32","author":"Versiani","year":"1983","journal-title":"Jornal Brasileiro de Psiquiatria"},{"key":"10.1002\/14651858.CD010677.pub2-BIB0169|cit169","first-page":"212","article-title":"Bretazenil: neuroendocrinological profile of a partial benzodiazepine agonist in patients suffering from panic disorder with agoraphobia","volume":"26","author":"Wiesner","year":"1993","journal-title":"Pharmacopsychiatry"},{"key":"10.1002\/14651858.CD010677.pub2-BIB0170|cit170","unstructured":"Woods WS Charney SD Silver MJ Krystal HJ Heninger RG Benzodiazepine receptor antagonist effects in panic disorder 141st Annual Meeting of the American Psychiatric Association Montreal, Quebec"},{"issue":"27","key":"10.1002\/14651858.CD010677.pub2-BIB0171|cit171","first-page":"728","article-title":"[ Clinical experiences with the new-generation anxiolytic agent cloxazolam: a double-blind study. ] Klinische Erfahrungen mit dem Anxiolytikum der neuen Generation: CloxazolamEine Doppelblindstudie","volume":"74","author":"Zmorski","year":"1985","journal-title":"Schweizerische Rundschau fur Medizin Praxis"},{"key":"10.1002\/14651858.CD010677.pub2-BIB0172|cit172","unstructured":"Placebo-controlled study of efficacy of imipramine, diazepam, baclofen and propranolol in patients with panic disorder Obozrenie Psikhiatrii Med Psikhologii Im V M Bekhtereva 1994 43-50"},{"key":"10.1002\/14651858.CD010677.pub2-BIB0173|cit173","first-page":"176-89","article-title":"Therapeutic of anxiety: a double blind clinical trial between alprazolam, oxazepam and placebo","volume":"1983","author":"Bernik","year":"1983","journal-title":"RBM Psiquiatr"},{"issue":"1","key":"10.1002\/14651858.CD010677.pub2-BIB0174|cit174","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1097\/00004714-199002000-00005","article-title":"The relationship of alprazolam dose to steady-state plasma concentrations","volume":"10","author":"Ciraulo","year":"1990","journal-title":"Journal of Clinical Psychopharmacology"},{"issue":"8","key":"10.1002\/14651858.CD010677.pub2-BIB0175|cit175","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/0006-3223(89)90287-4","article-title":"The significance of HPA axis disturbance in panic disorder","volume":"25","author":"Coryell","year":"1989","journal-title":"Biological Psychiatry"},{"issue":"2","key":"10.1002\/14651858.CD010677.pub2-BIB0176|cit176","doi-asserted-by":"crossref","first-page":"78-81","DOI":"10.17305\/bjbms.2005.3292","article-title":"Sertraline and alprazolam in the treatment of panic disorder","volume":"5","author":"Fisekovic","year":"2005","journal-title":"Bosnian Journal of Basic Medical Sciences"},{"key":"10.1002\/14651858.CD010677.pub2-BIB0177|cit177","unstructured":"Gladsjo JA Rapaport MH McKinney RA Rabin A Auerbach MD Judd LL Impact of alprazolam on neuropsychological functioning in panic disorder. 150th Annual Meeting of the American Psychiatric Association; 1997 May 17-22; San Diego, CA 1997"},{"key":"10.1002\/14651858.CD010677.pub2-BIB0178|cit178","unstructured":"Ipca Laboratories Ltd Mumbai Comparative evaluation of efficacy and safety of clonazepam-CR, alprazolam-XR and placebo in patients with panic disorder WHO International Clinical Trials Registry Platform. [http:\/\/apps.who.int\/trialsearch\/Trial.aspx?TrialID=CTRI\/2012\/01\/002315] 2012"},{"key":"10.1002\/14651858.CD010677.pub2-BIB0179|cit179","unstructured":"Picanco PE Bacellar BB Lobo-Ponte HM Fortaleza CB Clinical trials with a new anti-anxiety drug, lorazepam V World Congress of Psychiatry Mexico City 950"},{"key":"10.1002\/14651858.CD010677.pub2-BIB0180|cit180","unstructured":"Tesar EG Rosenbaum FJ Pollack HM Sachs SG Herman BJ Sidari NJ Panic disorder: clonezepam versus alprazolam and placebo. 141st Annual Meeting of the American Psychiatric Association; 1988 May 7-12; Montreal, Quebec 1988"},{"issue":"2","key":"10.1002\/14651858.CD010677.pub2-BIB0181|cit181","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1590\/S1516-31802003000200009","article-title":"Therapeutic response to benzodiazepine in panic disorder subtypes","volume":"121","author":"Valenca","year":"2003","journal-title":"Revista Paulista de Medicina (Sao Paulo Medical Journal)"},{"key":"10.1002\/14651858.CD010677.pub2-BIB0182|cit182","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1001\/jama.290.7.921","article-title":"Association of funding and conclusions in randomized drug trials: a reflection of treatment effect or adverse events?","volume":"290","author":"Als-Nielsen","year":"2003","journal-title":"JAMA"},{"key":"10.1002\/14651858.CD010677.pub2-BIB0183|cit183","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1136\/bmj.313.7066.1200","article-title":"Detecting skewness for summary information","volume":"313","author":"Altman","year":"1996","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD010677.pub2-BIB0184|cit184","volume-title":"Diagnostic and Statistical Manual of Mental Disorders","author":"American Psychiatric Association","year":"1994"},{"key":"10.1002\/14651858.CD010677.pub2-BIB0185|cit185","doi-asserted-by":"crossref","DOI":"10.1176\/appi.books.9780890423905.154688","volume-title":"American Psychiatric Association Practice Guideline for the Treatment of Panic Disorder","author":"American Psychiatric Association","year":"2009"},{"key":"10.1002\/14651858.CD010677.pub2-BIB0186|cit186","unstructured":"American Psychiatric Association Highlights of changes from DSM-IV-TR to DSM-5 www.dsm5.org\/Documents\/changes%20from%20dsm-iv-tr%20to%20dsm-5.pdf"},{"key":"10.1002\/14651858.CD010677.pub2-BIB0187|cit187","doi-asserted-by":"crossref","DOI":"10.1176\/appi.books.9780890425596","volume-title":"Diagnostic and Statistical Manual of Mental Disorders (DSM-5)","author":"American Psychiatric Association","year":"2013"},{"issue":"5","key":"10.1002\/14651858.CD010677.pub2-BIB0188|cit188","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1177\/0269881114525674","article-title":"Evidence-based pharmacological treatment of anxiety disorders, post-traumatic stress disorder and obsessive-compulsive disorder","volume":"28","author":"Baldwin","year":"2014","journal-title":"Journal of Psychopharmacology"},{"issue":"Suppl 8","key":"10.1002\/14651858.CD010677.pub2-BIB0189|cit189","first-page":"47","article-title":"Consensus statement on panic disorder from the International Consensus Group on Depression and Anxiety","volume":"59","author":"Ballenger","year":"1998","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD010677.pub2-BIB0190|cit190","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.4088\/JCP.v67n0914","article-title":"What is the threshold for symptomatic response and remission for major depressive disorder, panic disorder, social anxiety disorder, and generalized anxiety disorder?","volume":"67","author":"Bandelow","year":"2006","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD010677.pub2-BIB0191|cit191","doi-asserted-by":"crossref","first-page":"77","DOI":"10.3109\/13651501.2012.667114","article-title":"Guidelines for the pharmacological treatment of anxiety disorders, obsessive-compulsive disorder and posttraumatic stress disorder in primary care","volume":"16","author":"Bandelow","year":"2012","journal-title":"International Journal of Psychiatry in Clinical Practice"},{"issue":"3","key":"10.1002\/14651858.CD010677.pub2-BIB0192|cit192","doi-asserted-by":"crossref","first-page":"327","DOI":"10.31887\/DCNS.2015.17.3\/bbandelow","article-title":"Epidemiology of anxiety disorders in the 21st century","volume":"17","author":"Bandelow","year":"2015","journal-title":"Dialogues in clinical neuroscience"},{"issue":"2","key":"10.1002\/14651858.CD010677.pub2-BIB0193|cit193","doi-asserted-by":"crossref","first-page":"93","DOI":"10.31887\/DCNS.2017.19.2\/bbandelow","article-title":"Treatment of anxiety disorders","volume":"19","author":"Bandelow","year":"2017","journal-title":"Dialogues in Clinical Neuroscience"},{"issue":"3","key":"10.1002\/14651858.CD010677.pub2-BIB0194|cit194","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1017\/S1461145711000800","article-title":"Evidence-based pharmacotherapy of panic disorder: an update","volume":"15","author":"Batelaan","year":"2012","journal-title":"International Journal of Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD010677.pub2-BIB0195|cit195","first-page":"477","article-title":"Association between industry funding and statistically significant pro-industry findings in medical and surgical randomized trials","volume":"170","author":"Bhandari","year":"2004","journal-title":"Canadian Medical Association Journal"},{"issue":"9","key":"10.1002\/14651858.CD010677.pub2-BIB0196|cit196","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD011567.pub2","article-title":"Antidepressants and benzodiazepines for panic disorder in adults","author":"Bighelli","year":"2016","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"4","key":"10.1002\/14651858.CD010677.pub2-BIB0197|cit197","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD010676.pub2","article-title":"Antidepressants versus placebo for panic disorder in adults","author":"Bighelli","year":"2018","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD010677.pub2-BIB0198|cit198","first-page":"405","article-title":"The problem of therapeutic efficacy indices. Comparison of the indices and their use","volume":"54","author":"Boissel","year":"1999","journal-title":"Therapie"},{"issue":"1","key":"10.1002\/14651858.CD010677.pub2-BIB0199|cit199","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1097\/00004850-199503000-00006","article-title":"Serotonin uptake inhibitors are superior to imipramine and alprazolam in alleviating panic attacks: a meta-analysis","volume":"10","author":"Boyer","year":"1995","journal-title":"International Clinical Psychopharmacology"},{"issue":"5","key":"10.1002\/14651858.CD010677.pub2-BIB0200|cit200","doi-asserted-by":"crossref","first-page":"152","DOI":"10.18773\/austprescr.2015.055","article-title":"Management of benzodiazepine misuse and dependence","volume":"38","author":"Brett","year":"2015","journal-title":"Australian Prescriber"},{"key":"10.1002\/14651858.CD010677.pub2-BIB0201|cit201","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1176\/appi.ajp.160.8.1432","article-title":"Are benzodiazepines still the medication of choice for patients with panic disorder with or without agoraphobia?","volume":"160","author":"Bruce","year":"2003","journal-title":"American Journal of Psychiatry"},{"key":"10.1002\/14651858.CD010677.pub2-BIB0202|cit202","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1345\/aph.1D267","article-title":"Industry sponsorship and authorship of clinical trials over 20 years","volume":"38","author":"Buchkowsky","year":"2004","journal-title":"Annals of Pharmacotherapy"},{"key":"10.1002\/14651858.CD010677.pub2-BIB0203|cit203","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1001\/archpsyc.64.7.793","article-title":"Reduced gamma-aminobutyric acid(A)-benzodiazepine binding sites in insular cortex of individuals with panic disorder","volume":"64","author":"Cameron","year":"2007","journal-title":"Archives of General Psychiatry"},{"issue":"3","key":"10.1002\/14651858.CD010677.pub2-BIB0204|cit204","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/S0962-1849(05)80119-2","article-title":"An overview of the cognitive theory and treatment of panic disorder","volume":"2","author":"Clark","year":"1993","journal-title":"Applied and Preventive Psychology"},{"issue":"2","key":"10.1002\/14651858.CD010677.pub2-BIB0205|cit205","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1037\/0022-006X.61.2.317","article-title":"A meta-analysis of treatments for panic disorder","volume":"61","author":"Clum","year":"1993","journal-title":"Journal of Consulting and Clinical Psychology"},{"issue":"12","key":"10.1002\/14651858.CD010677.pub2-BIB0206|cit206","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1002\/da.22572","article-title":"Cross-national epidemiology of panic disorder and panic attacks in the world mental health surveys","volume":"33","author":"Jonge","year":"2016","journal-title":"Depression and Anxiety"},{"key":"10.1002\/14651858.CD010677.pub2-BIB0207|cit207","unstructured":"Deeks J Issues in the selection for meta-analyses of binary data. The 8th International Cochrane Colloquium; 2000 Oct 25-28; Cape Town, South Africa 2000"},{"issue":"1","key":"10.1002\/14651858.CD010677.pub2-BIB0208|cit208","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.eurpsy.2011.11.003","article-title":"Do benzodiazepines still deserve a major role in the treatment of psychiatric disorders? A critical reappraisal","volume":"28","author":"Dell\u2019osso","year":"2013","journal-title":"European Psychiatry"},{"issue":"1","key":"10.1002\/14651858.CD010677.pub2-BIB0209|cit209","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s00702-012-0811-1","article-title":"Revise the revised? New dimensions of the neuroanatomical hypothesis of panic disorder","volume":"120","author":"Dresler","year":"2013","journal-title":"Journal of Neural Transmission (Vienna)"},{"key":"10.1002\/14651858.CD010677.pub2-BIB0210|cit210","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1093\/ije\/31.1.140","article-title":"Meta-analyses involving cross-over trials: methodological issues","volume":"31","author":"Elbourne","year":"2002","journal-title":"International Journal of Epidemiology"},{"issue":"2","key":"10.1002\/14651858.CD010677.pub2-BIB0211|cit211","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1111\/pcn.12203","article-title":"Dependence on benzodiazepines in patients with panic disorder: a cross-sectional study","volume":"69","author":"Fujii","year":"2015","journal-title":"Psychiatry and Clinical Neurosciences"},{"key":"10.1002\/14651858.CD010677.pub2-BIB0212|cit212","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1093\/ije\/31.1.72","article-title":"Can we individualize the 'number needed to treat'? An empirical study of summary effect measures in meta-analyses","volume":"31","author":"Furukawa","year":"2002","journal-title":"International Journal of Epidemiology"},{"key":"10.1002\/14651858.CD010677.pub2-BIB0213|cit213","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1097\/00004850-200501000-00010","article-title":"Imputing response rates from means and standard deviations in meta-analysis","volume":"20","author":"Furukawa","year":"2005","journal-title":"International Clinical Psychopharmacology"},{"key":"10.1002\/14651858.CD010677.pub2-BIB0214|cit214","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.jclinepi.2005.06.006","article-title":"Imputing missing standard deviations in meta-analyses can provide accurate results","volume":"59","author":"Furukawa","year":"2000","journal-title":"Journal of Clinical Epidemiology"},{"issue":"10","key":"10.1002\/14651858.CD010677.pub2-BIB0215|cit215","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1002\/da.20532","article-title":"Evidence-based guidelines for interpretation of the Panic Disorder Severity Scale","volume":"26","author":"Furukawa","year":"2009","journal-title":"Depression and Anxiety"},{"key":"10.1002\/14651858.CD010677.pub2-BIB0216|cit216","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1176\/ajp.152.10.1438","article-title":"DSM-IV and the disappearance of agoraphobia without a history of panic disorder: new data on a controversial diagnosis","volume":"152","author":"Goisman","year":"1995","journal-title":"American Journal of Psychiatry"},{"key":"10.1002\/14651858.CD010677.pub2-BIB0217|cit217","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1176\/appi.ajp.157.4.493","article-title":"Neuroanatomical hypothesis of panic disorder, revised","volume":"157","author":"Gorman","year":"2000","journal-title":"American Journal of Psychiatry"},{"key":"10.1002\/14651858.CD010677.pub2-BIB0218|cit218","doi-asserted-by":"crossref","first-page":"363","DOI":"10.4088\/JCP.v67n0305","article-title":"The epidemiology of DSM-IV panic disorder and agoraphobia in the United States: results from the National Epidemiologic Survey on Alcohol and Related Conditions","volume":"67","author":"Grant","year":"2006","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD010677.pub2-BIB0219|cit219","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1016\/j.jclinepi.2011.03.017","article-title":"GRADE guidelines: 7. Rating the quality of evidence - inconsistency","volume":"64","author":"Guyatt","year":"2011","journal-title":"Journal of Clinical Epidemiology"},{"issue":"12","key":"10.1002\/14651858.CD010677.pub2-BIB0220|cit220","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1016\/j.jclinepi.2011.04.014","article-title":"GRADE guidelines: 8. Rating the quality of evidence - indirectness","volume":"64","author":"Guyatt","year":"2011","journal-title":"Journal of Clinical Epidemiology"},{"issue":"4","key":"10.1002\/14651858.CD010677.pub2-BIB0221|cit221","doi-asserted-by":"crossref","first-page":"2080","DOI":"10.1152\/jn.00998.2014","article-title":"The periaqueductal gray and descending pain modulation: why should we study them and what role do they play in chronic pain?","volume":"114","author":"Hemington","year":"2015","journal-title":"Journal of Neurophysiology"},{"key":"10.1002\/14651858.CD010677.pub2-BIB0222|cit222","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions","author":"Higgins","year":"2011"},{"issue":"10","key":"10.1002\/14651858.CD010677.pub2-BIB0223|cit223","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD011170.pub2","article-title":"Psychological therapies versus pharmacological interventions for panic disorder with or without agoraphobia in adults","author":"Imai","year":"2016","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD010677.pub2-BIB0224|cit224","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1001\/archpsyc.63.4.415","article-title":"The epidemiology of panic attacks, panic disorder, and agoraphobia in the National Comorbidity Survey Replication","volume":"63","author":"Kessler","year":"2006","journal-title":"Archives of General Psychiatry"},{"key":"10.1002\/14651858.CD010677.pub2-BIB0225|cit225","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1192\/bjp.bp.107.039966","article-title":"Prevalence of common mental disorders in general practice attendees across Europe","volume":"192","author":"King","year":"2008","journal-title":"British Journal of Psychiatry"},{"key":"10.1002\/14651858.CD010677.pub2-BIB0226|cit226","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1007\/BF02193476","article-title":"Delineation of two drug-responsive anxiety syndromes","volume":"5","author":"Klein","year":"1964","journal-title":"Psychopharmacologia"},{"issue":"1","key":"10.1002\/14651858.CD010677.pub2-BIB0227|cit227","first-page":"39","article-title":"Clinical trials in psychiatry: should protocol deviation censor patient data?","volume":"6","author":"Lavori","year":"1992","journal-title":"Neuropsychopharmacology"},{"issue":"17","key":"10.1002\/14651858.CD010677.pub2-BIB0228|cit228","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1002\/sim.4780141707","article-title":"A multiple imputation strategy for clinical trials with truncation of patient data","volume":"14","author":"Lavori","year":"1995","journal-title":"Statistics in Medicine"},{"key":"10.1002\/14651858.CD010677.pub2-BIB0229|cit229","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1136\/bmj.326.7400.1167","article-title":"Pharmaceutical industry sponsorship and research outcome and quality: systematic review","volume":"326","author":"Lexchin","year":"2003","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD010677.pub2-BIB0230|cit230","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1001\/archpsyc.55.8.715","article-title":"Decreased brain GABA(A)-benzodiazepine receptor binding in panic disorder: preliminary results from a quantitative PET study","volume":"55","author":"Malizia","year":"1998","journal-title":"Archives of General Psychiatry"},{"issue":"1","key":"10.1002\/14651858.CD010677.pub2-BIB0231|cit231","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1037\/0022-006X.59.1.184","article-title":"How \"blind\" are double-blind studies?","volume":"59","author":"Margraf","year":"1991","journal-title":"Journal of Consulting and Clinical Psychology"},{"issue":"9","key":"10.1002\/14651858.CD010677.pub2-BIB0232|cit232","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1097\/00005053-199009000-00003","article-title":"Treatment of panic and agoraphobia. An integrative review","volume":"178","author":"Mattick","year":"1990","journal-title":"Journal of Nervous and Mental Disease"},{"issue":"6","key":"10.1002\/14651858.CD010677.pub2-BIB0233|cit233","doi-asserted-by":"crossref","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement","volume":"6","author":"Moher","year":"2009","journal-title":"PLOS Medicine"},{"issue":"2","key":"10.1002\/14651858.CD010677.pub2-BIB0234|cit234","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1097\/00004714-198904000-00023","article-title":"Actual medication versus therapist guesses: in a blind study, how blind is blind?","volume":"9","author":"Munjack","year":"1989","journal-title":"Journal of Clinical Psychopharmacology"},{"key":"10.1002\/14651858.CD010677.pub2-BIB0235|cit235","volume-title":"Generalised Anxiety Disorder and Panic Disorder (With or Without Agoraphobia) in Adults [CG113]","author":"National Institute for Health and Care Excellence","year":"2011"},{"issue":"2","key":"10.1002\/14651858.CD010677.pub2-BIB0236|cit236","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1001\/jamapsychiatry.2014.1763","article-title":"Benzodiazepine use in the United States","volume":"72","author":"Olfson","year":"2015","journal-title":"JAMA Psychiatry"},{"issue":"3","key":"10.1002\/14651858.CD010677.pub2-BIB0237|cit237","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1136\/eb-2016-102412","article-title":"Prevalence, impact and treatment of generalised anxiety disorder in bipolar disorder: a systematic review and meta-analysis","volume":"19","author":"Preti","year":"2016","journal-title":"Evidence-Based Mental Health"},{"key":"10.1002\/14651858.CD010677.pub2-BIB0238|cit238","unstructured":"Nordic Cochrane Centre, The Cochrane Collaboration Review Manager 5 (RevMan 5) 2014"},{"issue":"3","key":"10.1002\/14651858.CD010677.pub2-BIB0239|cit239","doi-asserted-by":"crossref","first-page":"153","DOI":"10.3109\/08039489409081352","article-title":"Prediction of placebo response in panic disorder: A short review","volume":"48","author":"Rosenberg","year":"1994","journal-title":"Nordic Journal of Psychiatry"},{"key":"10.1002\/14651858.CD010677.pub2-BIB0240|cit240","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1590\/2237-6089-2015-0041","article-title":"Assessment of dependence and anxiety among benzodiazepine users in a provincial municipality in Rio Grande do Sul, Brazil","volume":"27","author":"Schallemberger","year":"2016","journal-title":"Trends in Psychiatry and Psychotherapy"},{"issue":"393","key":"10.1002\/14651858.CD010677.pub2-BIB0241|cit241","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1111\/j.1600-0447.1998.tb05973.x","article-title":"Benzodiazepine dependence and withdrawal: a review of the syndrome and its clinical management","volume":"98","author":"Schweizer","year":"1998","journal-title":"Acta Psychiatrica Scandinavica, Supplementum"},{"issue":"2","key":"10.1002\/14651858.CD010677.pub2-BIB0242|cit242","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s00127-009-0056-y","article-title":"Prevalence of mental disorders in primary care: results from the diagnosis and treatment of mental disorders in primary care study (DASMAP)","volume":"45","author":"Serrano-Blanco","year":"2010","journal-title":"Social Psychiatry and Psychiatric Epidemiology"},{"key":"10.1002\/14651858.CD010677.pub2-BIB0243|cit243","doi-asserted-by":"crossref","DOI":"10.1093\/oso\/9780195369250.001.0001","volume-title":"Anxiety Disorders in Adults: a Clinical Guide","author":"Starcevic","year":"2009"},{"key":"10.1002\/14651858.CD010677.pub2-BIB0244|cit244","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1007\/7854_2009_35","article-title":"Pharmacologic treatment of panic disorder","volume":"2","author":"Stein","year":"2010","journal-title":"Current Topics in Behavioral Neurosciences"},{"key":"10.1002\/14651858.CD010677.pub2-BIB0245|cit245","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18637\/jss.v036.i03","article-title":"Conducting meta-analyses in R with themetafor package","volume":"36","author":"Viechtbauer","year":"2010","journal-title":"Journal of Statistical Software"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD010677.pub2-BIB0246|cit246","first-page":"S13","article-title":"Antidepressants in panic disorder","volume":"14","author":"Wade","year":"1999","journal-title":"International Clinical Psychopharmacology"},{"issue":"1","key":"10.1002\/14651858.CD010677.pub2-BIB0247|cit247","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD005335.pub2","article-title":"Combined psychotherapy plus benzodiazepines for panic disorder","author":"Watanabe","year":"2009","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD010677.pub2-BIB0248|cit248","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1017\/S0033291700029986","article-title":"Meta-analysis of double-blind placebo-controlled trials of antidepressants and benzodiazepines for patients with panic disorders","volume":"21","author":"Wilkinson","year":"1991","journal-title":"Psychological Medicine"},{"issue":"7","key":"10.1002\/14651858.CD010677.pub2-BIB0249|cit249","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD010677","article-title":"Benzodiazepines versus placebo for panic disorder in adults","author":"Guaiana","year":"2013","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cochranelibrary.com\/cdsr\/doi\/10.1002\/14651858.CD010677.pub2\/epdf\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,9]],"date-time":"2021-08-09T18:47:09Z","timestamp":1628534829000},"score":1,"resource":{"primary":{"URL":"https:\/\/doi.wiley.com\/10.1002\/14651858.CD010677.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Common Mental Disorders Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2019,3,28]]},"references-count":249,"URL":"https:\/\/doi.org\/10.1002\/14651858.cd010677.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3,28]]}}}